Xentria, Inc.

Xentria, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in 2020, Xentria works across biopharmaceutics communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from “centrality”, is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships. Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability.

Company Details

Employees
25
Founded
-
Address
8700 W Bryn Mawr Ave,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Chicago, Illinois
Looking for a particular Xentria, Inc. employee's phone or email?

Xentria, Inc. Questions

News

Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development - PR Newswire

Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development PR Newswire

Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth - PR Newswire

Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth PR Newswire

Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally - PR Newswire

Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally PR Newswire

Xentria: redefining collaborative approaches to advance R&D - Nature

Xentria: redefining collaborative approaches to advance R&D Nature

Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America - Business Wire

Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America Business Wire

Xentria and Meitheal enter sarcoidosis therapy licensing deal - Pharmaceutical Technology

Xentria and Meitheal enter sarcoidosis therapy licensing deal Pharmaceutical Technology

Meitheal bets there is still life in TNF inhibitors, paying Xentria $45M for lung disease therapy - Fierce Biotech

Meitheal bets there is still life in TNF inhibitors, paying Xentria $45M for lung disease therapy Fierce Biotech

Enrollment complete in XTMAB-16 Phase 1/2 trial for pulmonary... - Sarcoidosis News

Enrollment complete in XTMAB-16 Phase 1/2 trial for pulmonary... Sarcoidosis News

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal - Business Wire

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal Business Wire

Xentria gets US FDA orphan drug designation for XTMAB-16 in sarcoidosis - Express Pharma

Xentria gets US FDA orphan drug designation for XTMAB-16 in sarcoidosis Express Pharma

Top Xentria, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant